14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MYCG vs SEPM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, FT Vest U.S. Equity Max Buffer ETF - September (SEPM) is the stronger overall head-to-head candidate over SPDR SSGA My2027 Corporate Bond ETF (MYCG) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). MYCG carries a Unified Composite Score of 53.7/100 (HOLD) at $24.88 (N/M Forward P/E, N/A operating margin), whereas SEPM carries 46.4/100 (HOLD) at $32.83 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While MYCG currently prints a higher short-term Unified Composite Score (53.7/100 HOLD vs. SEPM 46.4/100 HOLD), SEPM captures the overall institutional head-to-head verdict (1–2 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
Technical & Structure Timing Caution: MYCG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.8); meanwhile SEPM is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MYCG vs SEPM. Trailing 12-month operating profitability (MYCG N/A vs SEPM N/A) and valuation multiples (MYCG N/M vs SEPM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MYCG vs SEPM Key Questions & Quantitative Answers
As of Nov 20, 2026, FT Vest U.S. Equity Max Buffer ETF - September (SEPM) is the stronger overall head-to-head candidate over SPDR SSGA My2027 Corporate Bond ETF (MYCG) in the Tradestie Institutional Equity Comparison Engine, winning 1–2 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). MYCG carries a Unified Composite Score of 53.7/100 (HOLD) at $24.88 (N/M Forward P/E, N/A operating margin), whereas SEPM carries 46.4/100 (HOLD) at $32.83 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While MYCG currently prints a higher short-term Unified Composite Score (53.7/100 HOLD vs. SEPM 46.4/100 HOLD), SEPM captures the overall institutional head-to-head verdict (1–2 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: MYCG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.8); meanwhile SEPM is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MYCG and SEPM split Growth & Scale metrics: MYCG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SEPM at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, MYCG generates N/A in USD-normalized revenue versus N/A for SEPM. In operating R&D and SG&A reinvestment, MYCG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SEPM.
MYCG and SEPM trade at balanced relative valuation multiples. MYCG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SEPM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYCG (N/A ROE) versus SEPM (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, MYCG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 2% Vol realized risk). By comparison, SEPM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.15β · 4% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.